This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Dorian, P. PubMed Articles by Dorian, P. Related Collections Related Articles

CLINICAL RESEARCH: HEART RHYTHM DISORDER

Azimilide Reduces Emergency Department Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial

Paul Dorian, MD, FACC^_*,_*, Hussein R. Al-Khalidi, PhD, FAHA, Stefan H. Hohnloser, MD, FACC, Jose M. Brum, MD, MSc, Preston M. Dunnmon, MD, FACC, Craig M. Pratt, MD, FACC, Michael J. Holroyde, PhD, Peter Kowey, MD, FACC^|| on behalf of the SHIELD (SHock Inhibition Evaluation with AzimiLiDe) Investigators

^_* Division of Cardiology, St. Michael's Hospital/University of Toronto, Toronto, Ontario, Canada
Health Care Research Center, Procter & Gamble Pharmaceuticals, Cincinnati, Ohio
Department of Cardiology, Division of Electrophysiology, J.W. Goethe-University, Frankfurt, Germany
Methodist DeBakey Heart Center, Houston, Texas
^|| Division of Cardiovascular Diseases, Jefferson Medical College, Philadelphia, Pennsylvania

Manuscript received March 5, 2008; revised manuscript received April 24, 2008, accepted May 21, 2008.

^_* Reprint requests and correspondence: Dr. Paul Dorian, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada (Email: dorianp{at}smh.toronto.on.ca).

Objectives: The goal of this study was to determine whether azimilide, as compared with placebo, will reduce the number of emergency department (ED) visits and hospitalizations caused by arrhythmias or cardiac events in patients with an implantable cardioverter-defibrillator (ICD).

Background: Patients with an ICD may require ED visits and hospitalizations because of arrhythmias, which trigger ICD therapies. The effect of adjunctive antiarrhythmic therapy on these outcomes is not known.

Methods: A total of 633 patients with an ICD were randomized in the SHIELD (SHock Inhibition Evaluation with AzimiLiDe) trial, a blinded, placebo-controlled randomized trial of the investigational class III antiarrhythmic azimilide (75 and 125 mg/day), and, prospectively, cardiac and arrhythmic ED visits and hospitalization data were collected over 1 year.

Results: All patients had symptomatic sustained ventricular tachycardia (72%) or ventricular fibrillation (28%) before study entry. Overall, 44% (n = 276) experienced at least 1 cardiac ED visit or hospitalization. Among 214 patients assigned to placebo, 38.3% had at least 1 arrhythmic-related ED visit or hospitalization compared with 21.8% of 220 patients assigned to 75-mg azimilide (p < 0.001) and 27.6% of 199 patients assigned to 125 mg azimilide (p < 0.05). Symptomatic ventricular tachycardia treated by antitachycardia pacing, shocks, and shocks plus symptomatic arrhythmias were significant predictors of cardiac-related ED visits or hospitalizations (relative risk: 2.0, 3.0, and 3.1, respectively). In a stepwise logistic regression model, the presence of congestive heart failure (New York Heart Association functional class II/III) was the only additional independent predictor of cardiac ED visits or hospitalizations.

Conclusions: Azimilide significantly reduces the number of ED visits and hospitalizations in patients with an ICD at high risk of arrhythmias.

Key Words: azimilide dihydrochloride • recurrent events • implantable cardioverter-defibrillator • antiarrhythmic therapy • ventricular tachycardia storms • hospitalization

Abbreviations and Acronyms   ATP = antitachycardia pacing   CHF = congestive heart failure   ED = emergency department   EF = ejection fraction   HR = hazard ratio   ICD = implantable cardioverter-defibrillator   MI = myocardial infarction   NYHA = New York Heart Association   TdP = torsades de pointes   VF = ventricular fibrillation   VT = ventricular tachycardia

Related Articles

Azimilide: Another Effort to Prevent Implantable Cardioverter-Defibrillator Shocks and Their Sequelae: Why it Is Important and How it Works

David S. Cannom and Brett Gidney
J. Am. Coll. Cardiol. 2008 52: 1084-1085. [Full Text] [PDF]

This article has been cited by other articles:

				D. S. Cannom and B. Gidney Azimilide: Another Effort to Prevent Implantable Cardioverter-Defibrillator Shocks and Their Sequelae: Why it Is Important and How it Works J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1084 - 1085. [Full Text] [PDF]